ISSN: 1859 - 2872
Early results of hypofractionated radiotherapy for localized prostate cancer patients
Main Article Content
Keywords
Abstract
Objective: To evaluate the early results of hypofractionated radiotherapy in prostate cancer patients with localized stage. Subject and method: A prospective, uncontrolled intervention study on 30 prostate cancer patients with stage T1-3bN0M0 underwent radical radiotherapy at 60-65Gy in 20-25 fractions with or without endocrine therapy. The Kaplan-Meier curve was used to estimate PSA control and survival rates. Evaluation of early side effects according to CTCAE 5.0 criteria. Result: Median follow-up time was 22.5 months. PSA recurrence-free survival and disease-free survival at 30 months were 92.3% and 90.0%, respectively. Most of the early lower digestive tract and urinary side effects were grade 1-2, including proctitis (40.0%), cystitis (33.4%), and enteritis (10.0%); no early side effects were grade 3 or higher. Conclusion: Hypofractionated radiotherapy in localized prostate cancer has promising results and is safe.
Article Details
References
2. Aydh A, Motlagh RS, Abufaraj M et al (2022) Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. Arab J Urol 20(2): 71-80.
3. Incrocci L, Wortel RC, Alemayehu WG et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology 17(8): 1061-1069.
4. Brenner DJ and Hall EJ (2018) Hypofractionation in prostate cancer radiotherapy. Transl Cancer Res 7(6): 632-639.
5. Bruner DW, Pugh SL, Lee WR et al (2016) NRG Oncology/RTOG 0415, phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer: Prostate-specific quality of life results. International Journal of Radiation Oncology, Biology, Physics 96(2): 2-3.
6. Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The Lancet Oncology 17(8): 1047-1060.
7. Catton CN, Lukka H, Gu CS et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. JCO 35(17): 1884-1890.
8. Partin Nomogram (2023) Estimate Likelihood of Prostate Cancer Stage Johns Hopkins Brady Urological Institute.
9. Geara FB, Bulbul M, Khauli RB et al (2017) Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation. Radiat Oncol 12(1): 149.
10. Kazama A, Saito T, Takeda K et al (2019) Achieving PSA < 0.2ng/ml before radiation therapy is a strong predictor of treatment success in patients with high-risk locally advanced prostate cancer. Prostate Cancer: 1-6.
Article Sidebar
